Riskpilot← Back to searchSign inGet full accessAcet Medica AB
ABIn liquidationOrg 5590724299Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK 0
+100% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 0 | +100% |
| Total assets | SEK 28K | +0% |
| Equity | SEK 28K | +0% |
| Employees | 0 | — |
Legal name
Acet Medica AB
Org number
5590724299
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11 augusti 2016
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Utveckla patentbara läkemedel och medicinsk utrustning samt sälja licenser till återförsäljare alt. tillverkare över läkemedel.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −192 | −320 | −109 | −17 | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −192 | −320 | −109 | −17 | 0 |
| Net financials | −36 | −14 | −506 | −11 | — |
| Profit before tax | −227 | −334 | −362 | −28 | 0 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −227 | −334 | −362 | −28 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 174 | 251 | 95 | 28 | 28 |
| Equity | 543 | 209 | 56 | 28 | 28 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 631 | 43 | 39 | 0 | 0 |
| Total debt | 1 631 | 43 | 39 | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
OR Chief Auditor | Chief Auditor | 2020 |
UP Liquidator | Liquidator | 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Chairman | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2023 | |
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 95% | 95% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AUXESIS PHARMA HOLDING AB (publ)
Acet Medica AB Board members of Acet Medica AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olov Rickard Tony Sjölund | Chief Auditor | 0 companies |
| Ulf Peter Hedberg | Liquidator | 0 companies |
| Roar Adelsten | Chairman | 0 companies |
| Helena Adelsten | Deputy Board Member | 0 companies |
| May Martinsen | Board of Directors | 0 companies |